Zolbetuximab (Zolbetuximab) - Detailed instructions for Vyloy: Indications and clinical applications

Zolbetuximab (Zolbetuximab)-Vyloy is an important breakthrough in the treatment of gastric cancer in recent years, and its indications and mechanism of action have attracted much attention. According to the drug instructions and clinical research data, zotuximab is mainly used to treat CLDN18.2-positive advanced or metastatic gastric cancer and gastroesophageal junction adenocarcinoma. This indication was determined based on its unique mechanism of action and significant efficacy in clinical trials, providing a new treatment option for specific patient groups.

CLDN18.2 (Claudin 18.2) is a protein specifically expressed in gastric cancer cells, but its expression is limited in normal tissues. Zotuximab, as a monoclonal antibody targeting CLDN18.2, can accurately recognize and bind to this target, thereby exerting anti-tumor effects. Its mechanism of action includes directly inhibiting the growth and proliferation of tumor cells, and further killing tumor cells through immune mechanisms such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). This dual mechanism of action allows zotuximab to exhibit significant therapeutic effects in gastric cancer patients with high CLDN18.2 expression.

In clinical studies, zotuximab combined with standard chemotherapy regimens (such asCAPOX or FOLFOX) has demonstrated significant efficacy in the treatment of patients with CLDN18.2-positive advanced or metastatic gastric cancer and gastroesophageal junction adenocarcinoma. Research data showed that compared with chemotherapy alone, patients treated with zotuximab-Vyloy had significant improvements in progression-free survival (PFS) and overall survival (OS). For example, in the FAST trial, patients who received the zotuximab combination had a median OS of 13.2 months, compared with 8.4 months in the chemotherapy alone group. This result not only verifies the clinical value of zotuximab, but also provides new hope for gastric cancer patients.

It is important for patients to understand the indications for their medications. The indications of zotuximab clearly point to CLDN18.2-positive gastric cancer patients, which means that before using the drug, patients need to confirm the expression level of CLDN18.2 in tumor tissue through immunohistochemistry (IHC) testing. This precision medicine strategy not only improves the pertinence of treatment, but also avoids unnecessary drug exposure and potential side effects. In actual clinical applications, doctors will formulate personalized treatment plans based on the patient's test results and overall health status to ensure the safety and effectiveness of the treatment.

The indications of zotuximab are not limited to first-line treatment, and its potential in second-line and subsequent treatment is also being actively explored. As more clinical data accumulate and treatment experience becomes richer, the scope of application of zotuximab may be further expanded. For example, there are currently studies exploring its application in the neoadjuvant treatment of locally advanced gastric cancer, and preliminary results show that it has good safety and efficacy. These studies provide more possibilities for the clinical application of zotuximab and bring more treatment options to patients with gastric cancer.

In general, the indications of zotuximab embody the concept of precision medicine. By targeting the specific marker CLDN18.2, zotuximab provides an efficient and safe treatment option for specific patient groups. With its promotion and application worldwide, it is believed that more gastric cancer patients will benefit from it. At the same time, the success of zotuximab also encourages scientific researchers to continue to explore the possibility of more targeted treatments and bring more breakthroughs in the field of tumor treatment. For patients and medical workers, understanding the indications and mechanisms of action of drugs not only helps to formulate the best treatment plan, but also provides an important basis for improving patient prognosis.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e7695a21-abb6-47ac-93f8-0ece5a9c4409